Mental Health America Response to New England Journal of Medicine Study, "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy"
Contact: Eileen Sexton, (703) 837-4783 or esexton@mentalhealthamerica.net
ALEXANDRIA, Va. (January 17, 2008) - Mental Health America, one of the nation's leading mental health advocacy groups, views the U.S. Food and Drug Administration's study of antidepressant trials published today in the New England Journal Medicine as a diligent measure, but cautions that this easily misinterpreted study not discourage people with depression from seeking appropriate care and evidence-based treatments that work for them.
"Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy," which appears in today's issue of the NEJM, surveys the results of both published and unpublished antidepressant FDA studies.
"This is a very important paper, and we applaud the FDA for moving toward greater transparency," said David Shern, Ph.D., president and CEO of Mental Health America. "It is critical, however, that people understand that antidepressants do work and continue to help millions of Americans recover from depression and other mental health conditions."
"Historically, papers that get published have been those with positive results. This study highlights what is known as the "waste basket" problem in which studies with positive outcomes are more likely to be published than those with neutral or negative outcomes," added Shern. "This study is a diligent follow-up detailing estimated effects and perhaps the oversimplification of the effects of antidepressants."
The fact remains, antidepressants do work and help millions of Americans to recover.
Mental Health America is the country's leading nonprofit dedicated to helping all people live mentally healthier lives. With our more than 320 affiliates nationwide, we represent a growing movement of Americans who promote mental wellness for the health and well-being of the nation - everyday and in times of crisis.
###
